Allogene Therapeutics Inc

Ouvert

SecteurSoins de santé

2.04 -3.77

Résumé

Variation du prix de l'action

24h

Actuel

Min

2.03

Max

2.17

Chiffres clés

By Trading Economics

Revenu

-3.8M

-43M

BPA

-0.18

Employés

150

EBITDA

-91K

-39M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+307.11% upside

Dividendes

By Acuity

Prochains Résultats

12 août 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-51M

735M

Ouverture précédente

5.81

Clôture précédente

2.04

Sentiment de l'Actualité

By Acuity

57%

43%

271 / 342 Classement par Healthcare

Allogene Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

1 juil. 2026, 23:52 UTC

News
Correlated Moves
Social Media

Meta Platforms Inc. shares fell in after-market trading amid a broader tech market downturn, despite earlier gains on plans for a cloud computing business.

1 juil. 2026, 23:51 UTC

Social Media
News
Correlated Moves
ETF Constituents

Invesco QQQ Trust trading lower after Nasdaq 100 decline, reflecting a market shift away from technology stocks. Notable trades occurred at $737.25.

1 juil. 2026, 23:36 UTC

Correlated Moves
News

Ethereum is trading higher, buoyed by Bitcoin's recent gains. Earlier in the session, Ethereum peaked before pulling back slightly but has since regained ground.

1 juil. 2026, 23:36 UTC

News
Social Media

AMD shares are higher in after-market hours following a $36 million equity award announcement for CEO Lisa T. Su and positive discussions at HPE Discover 2026.

1 juil. 2026, 23:36 UTC

News
Correlated Moves

Ethereum is trading higher, supported by Bitcoin's recent strong move. It pulled back slightly from earlier session highs but remains above Tuesday's close.

1 juil. 2026, 23:31 UTC

News

United States Oil Fund LP advances in after-market trading, despite lower oil prices and mixed global equity performance. No specific news identified for the move.

1 juil. 2026, 23:16 UTC

Correlated Moves
News

Qualcomm Inc. shares rose in after-market trading, reflecting a modest gain since Wednesday's close, amid KLA Corp's price increase and recent index removals.

1 juil. 2026, 23:06 UTC

News
ETF Constituents

Vanguard Growth ETF declines in after-market trading, reversing earlier gains. Broader market faces pressure from economic data and geopolitical tensions.

1 juil. 2026, 23:06 UTC

Social Media
News
ETF Constituents

The SPDR Dow Jones Industrial Average ETF Trust declined slightly in after-market hours, reflecting broader market trends and mixed investor sentiment.

1 juil. 2026, 23:06 UTC

News
Correlated Moves
ETF Constituents

The Nasdaq 100 Index shows slight gains in after-market hours, while the Vanguard Information Technology ETF remains roughly flat amid stable trading conditions.

1 juil. 2026, 22:51 UTC

News

Buy rating upgrade from Guggenheim boosts CHKP in after-market.

1 juil. 2026, 20:07 UTC

News
Social Media

American Airlines shares rise as Bernstein raises price target to $23. FAA's approval for supersonic flights may boost investor sentiment.

1 juil. 2026, 20:07 UTC

News

The Nikkei 225 Index is lower in after-market hours, reflecting significant volatility amid broader market sell-offs in technology stocks. No specific news was identified.

1 juil. 2026, 20:05 UTC

Correlated Moves
ETF Constituents
News

The iShares MSCI United Kingdom ETF is lower today amid reduced Bank of England rate hike expectations and a decline in the U.K. Manufacturing PMI.

1 juil. 2026, 20:04 UTC

Macro News
Macro Event
ETF Constituents
News

The Communication Services Select Sector SPDR Fund is rising amid a broader market rally, driven by strong gains in Meta Platforms and the overall sector.

1 juil. 2026, 20:04 UTC

Social Media
News
Macro Event
ETF Constituents

VanEck Gold Miners ETF declines as broader market dynamics weigh on investor sentiment, despite a rise in spot gold prices to $4,085 an ounce.

1 juil. 2026, 20:04 UTC

Social Media
News
ETF Constituents

iShares China Large-Cap ETF gains amid positive sentiment following the China foreign minister's remarks on U.S. relations and strong performance from constituent stocks.

1 juil. 2026, 20:04 UTC

Correlated Moves
News
Event
Macro Event
Social Media

iShares 20+ Year Treasury Bond ETF declines amid rising Treasury yields and comments from Federal Reserve Chair Kevin Warsh on high prices. The ETF went ex-dividend today at $0.31803.

1 juil. 2026, 20:03 UTC

News

Piper Sandler raised Illumina's price target to $200, contributing to shares trading higher today. The company also expanded its board with a new appointment.

1 juil. 2026, 20:03 UTC

Macro Event
News

Willis Towers Watson PLC launched its expanded CyMax Facility for cyber insurance aimed at SMEs in the EMEA region, boosting shares during Wednesday's session.

1 juil. 2026, 20:03 UTC

News
Correlated Moves

NXP Semiconductors NV's stock is lower amid negative assessment from StockStory, citing revenue concerns and lagging growth compared to industry averages.

1 juil. 2026, 20:03 UTC

Social Media
News

Adobe Inc. is trading higher during Wednesday's session, with analysts suggesting potential for recovery amid ongoing interest in the software sector despite recent challenges.

1 juil. 2026, 20:03 UTC

Social Media
News

Microsoft's stock rises on a five-year partnership with Haleon to enhance AI capabilities. A Jefferies survey shows Azure gaining traction over AWS.

1 juil. 2026, 20:02 UTC

News

Align Technology Inc. shares are higher as the company addresses an antitrust investigation and announces plans for its second-quarter 2026 financial results.

1 juil. 2026, 20:02 UTC

Macro Event
Social Media
News

Automatic Data Processing's stock rose following the ADP National Employment Report, which showed a 98,000 increase in private sector jobs for June.

1 juil. 2026, 20:02 UTC

Correlated Moves
News

Analog Devices Inc. shares are lower today, impacted by a significant decline in the semiconductor sub-sector and broader market volatility.

1 juil. 2026, 19:56 UTC

Correlated Moves
News

The U.S. dollar is near two-week lows, impacting the Invesco Currencyshares Japanese Yen Trust, which is trading roughly flat amid ongoing geopolitical tensions.

1 juil. 2026, 19:56 UTC

Macro Event
Correlated Moves
ETF Constituents
Macro News
News

Energy Select Sector SPDR Fund declines amid broader energy sector downturn and falling crude oil prices. ExxonMobil and Schlumberger contribute to negative performance.

1 juil. 2026, 19:51 UTC

Social Media
News
Macro Event

Cognizant Technology Solutions shares rise following the launch of Cognizant Neuro AI Trust, despite HSBC lowering its price target to $68 from $80.

1 juil. 2026, 19:47 UTC

Correlated Moves
Social Media
News

Alphabet Inc shares are higher as the company surpasses its $1 billion investment target in Africa, despite mixed social media sentiment regarding recent legal challenges.

Comparaison

Variation de prix

Allogene Therapeutics Inc prévision

Objectif de Prix

By TipRanks

307.11% hausse

Prévisions sur 12 Mois

Moyen 8.59 USD  307.11%

Haut 14 USD

Bas 3.85 USD

Basé sur 13 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

13 ratings

11

Achat

2

Maintien

0

Vente

Sentiment

By Acuity

271 / 342Classement par Soins de santé

Sentiment de l'Actualité

Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
help-icon Live chat